|Recent freebie editorial on inhaled insulin:|
Notable for the sentence:
"Formation of anti-insulin antibodies is higher with inhaled insulin, and although this is dismissed as not affecting insulin requirement over time, older diabetologists will remember the drive to reduce insulin antibody formation, with the fears that antibodies delay and render unpredictable insulin absorption and even that antibody-antigen complexes may increase risk of microvascular disease."
I think this will torpedo Exubera, too, unless long term study data that does not reflect the Novo/Aradigm experience is also submitted. I hear that relevant study data was submitted by Pfizer to EMEA, but I thought these long term studies were still ongoing.